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Randomized Multicenter Comparison of Conventional
Anticoagulation Versus Antiplatelet Therapy in Unplanned
and Elective Coronary Stenting
The Full Anticoagulation Versus Aspirin and Ticlopidine
(FANTASTIC) Study
Michel E. Bertrand, MD; Victor Legrand, MD; Jean Boland, MD; Eckart Fleck, MD;
Johannes Bonnier, MD; Hakan Emmanuelson, MD; Matty Vrolix, MD; Luc Missault, MD;
Sergio Chierchia, MD; Michele Casaccia, MD; Luigi Niccoli, MD;
Ali Oto, MD; Christopher White, MD; Michael Webb-Peploe, MD;
Eric Van Belle, MD; Euge`ne P. McFadden, MRCP
Background—Dual therapy with ticlopidine and aspirin has been shown to be as effective as or more effective than
conventional anticoagulation in patients with an optimal result after implantation of intracoronary metallic stents.
However, the safety and efficacy of antiplatelet therapy alone in an unselected population has not been evaluated.
Methods—Patients were randomized to conventional anticoagulation or to treatment with antiplatelet therapy alone.
Indications for stenting were classified as elective (decided before the procedure) or unplanned (to salvage failed
angioplasty or to optimize the results of balloon angioplasty). After stenting, patients received aspirin and either
ticlopidine or conventional anticoagulation (heparin or oral anticoagulant). The primary end point was the occurrence
of bleeding or peripheral vascular complications; secondary end points were cardiac events (death, infarction, or stent
occlusion) and duration of hospitalization.
Results—In 13 centers, 236 patients were randomized to anticoagulation and 249 to antiplatelet therapy. Stenting was
elective in 58% of patients and unplanned in 42%. Stent implantation was successfully achieved in 99% of patients. A
primary end point occurred in 33 patients (13.5%) in the antiplatelet group and 48 patients (21%) in the anticoagulation
group (odds ratio50.6 [95% CI 0.36 to 0.98], P50.03). Major cardiac-related events in electively stented patients were
less common (odds ratio50.23 [95% CI 0.05 to 0.91], P50.01) in the antiplatelet group (3 of 123, 2.4%) than the
anticoagulation group (11 of 111, 9.9%). Hospital stay was significantly shorter in the antiplatelet group (4.363.6 versus
6.463.7 days, P50.0001).
Conclusions—Antiplatelet therapy after coronary stenting significantly reduced rates of bleeding and subacute stent
occlusion compared with conventional anticoagulation. (Circulation. 1998;98:1597-1603.)
Key Words: stents n antiplatelet agents n anticoagulants
Intracoronary implantation of permanent metallic stents,introduced more than a decade ago, failed to achieve
widespread acceptance because of high rates of stent occlu-
sion and peripheral vascular complications. Two recent major
randomized trials1,2 showed that elective stent implantation
reduced clinical and angiographic restenosis in selected
patients. Despite the intensive anticoagulation regimen used
(heparin followed by oral anticoagulation), stent occlusion
still occurred in 3% to 5% of stented segments, and major
bleeding was frequently observed (15% to 18%). Finally, the
extended hospital stay required for therapeutic anticoagula-
tion or for treating complications negated the potential
economic advantage of the lower restenosis rate.
Two major advances have contributed to the increased use
of coronary stenting in recent years. First, there is evidence
that stent occlusion frequently results from inadequate stent
impaction and that high-pressure (12 to 15 atm) stent deploy-
ment significantly reduces the rate of stent occlusion.3 Sec-
ond, it has been demonstrated that antiplatelet therapy alone
was at least as effective as full anticoagulation in patients
with an optimal angiographic result after stent implantation.4,5
We undertook a randomized multicenter trial to compare
aggressive antiplatelet treatment to anticoagulation after im-
plantation of a Wiktor stent (Medtronic). The trial was
intentionally designed to compare the 2 treatments in a
patient population representative of that encountered in cur-
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rent clinical practice. Thus, treatment allocation was per-
formed before attempted stent implantation; all patients in
whom stent implantation was deemed necessary (whether
elective or unplanned) were eligible for inclusion; and finally,
all patients continued in the trial even if the final result after
stent implantation was suboptimal.
The primary objective of the study was to determine
whether aggressive treatment with antiplatelet drugs signifi-
cantly reduced the rate of bleeding complications compared
with that observed with full anticoagulation. The secondary
objective was to establish that the antiplatelet regimen did not
compromise stent patency by increasing the rate of acute or
subacute occlusion.
Methods
Inclusion and Exclusion Criteria
and Randomization
All patients in whom planned or unplanned stent implantation was
attempted were eligible for inclusion. Thus, patients scheduled for
elective stent implantation, those in whom stent implantation was
performed for a suboptimal result after balloon angioplasty, or those
for whom it was required as a bailout procedure after failed balloon
angioplasty were potential candidates for inclusion.
The exclusion criteria were similar to those for conventional
anticoagulation after stent implantation. Patients excluded were
those with known bleeding disorders, thrombocytopenia (,150 000/
mm3), recent (,6 months) gastrointestinal bleeding, recent cerebro-
vascular accident, recent intracranial or eye surgery, severe hepatic
or renal dysfunction, malignant hypertension, angiographic evidence
of thrombus at the proposed stent site, history of allergy to aspirin or
ticlopidine, history of heparin-related thrombocytopenia, or systemic
disease that significantly limited life expectancy.
Randomization was performed before angioplasty for elective
procedures and before stent implantation for unplanned stent implan-
tation by telephoning a central randomization center. The random-
ization sequence was established before the study began. The Ethical
Committee of each participating center approved the protocol and all
patients gave written informed consent.
Stent Implantation Procedure
Before intervention, patients were pretreated with aspirin (100 to 300
mg) at the discretion of the investigator. In addition, a bolus of
heparin (10 000 IU) was administered just before angioplasty, with
supplemental boluses (5000 IU) for each additional hour of proce-
dural time. Stent implantation was performed after balloon predila-
tation. Subsequently, a premounted Wiktor stent with a diameter
equivalent to or slightly (,10%) greater than the mean reference
diameter of the adjacent vessel was deployed at the nominal balloon
inflation pressure. Subsequently, a final inflation with a noncompli-
ant or semicompliant balloon at high pressure (.10 atm) was
performed. When required, 2 or more stents were implanted to
achieve an optimal angiographic result.
Stent placement was classified as elective when the decision to
implant a stent was made before the procedure. Randomization was
performed in these patients before the angioplasty procedure. Un-
planned stent implants were those performed for a suboptimal result
(residual stenosis.40%, visual estimate) with or without dissection
grade B or C or for failed angioplasty (dissection grade D1, D2, E,
or F).6 Randomization was performed as soon as the decision to
implant a stent had been taken. After the procedure, no further
heparin was given to patients who left the catheterization laboratory
before 2 PM, and their femoral artery sheaths were removed 4 hours
later. In the remaining patients, the sheaths were removed the
following day. These patients received an intravenous infusion of
heparin (1000 IU/h) 6 AM the next day. The sheaths were removed 4
hours after discontinuation of heparin.
Antiplatelet and Anticoagulation Regimens
After stent implantation, patients randomized to antiplatelet therapy
(group A) received their first dose of ticlopidine (500 mg) in the
catheterization laboratory. Patients were discharged on ticlopidine
(250 mg BID) for 6 weeks, and aspirin (100 to 325 mg daily) for life.
Patients randomized to conventional anticoagulation (group B) were
started on oral anticoagulant immediately after stent implantation.
After removal of the sheaths and after hemostasis, they received a
bolus of heparin (2500 IU) followed by a continuous infusion of
1000 IU/h that was adjusted to achieve a target activated partial
thromboplastin time value of 2.0 times to 2.5 times control. The daily
dose of oral anticoagulant was adjusted to achieve stable oral
anticoagulation. The target international normalized ratio (INR) was
between 2.5 and 3.0. When the target INR had been documented on
2 consecutive days, heparin was discontinued. At discharge, patients
were placed on oral anticoagulants for 6 weeks and aspirin (100 to
325 mg) for life.
Follow-Up
An ECG was recorded before the procedure, immediately after the
procedure, and before discharge. The day after the procedure and
before discharge, blood samples were obtained for measurement of






n (%) (n5230) P
Age, 6SD 60.0610.8 60.3610.4
Men 197 (81.5) 185 (80.4) 0.77
Current smokers 78 (32.5) 63 (27.4) 0.22
Former smokers 109 (44.9) 98 (42.6) 0.62
Insulin-dependent diabetes 8 (3.3) 6 (2.6) 0.66
Non–insulin-dependent diabetes 29 (12.3) 28 (12.2) 0.95
Hypertension (.160/90 mm Hg) 79 (32.5) 74 (32.2) 0.93
Hypercholesterolemia (.240 mg) 115 (47.7) 101 (43.9) 0.40
Family history of coronary disease 116 (48.1) 103 (44.8) 0.46
TABLE 2. Cardiac History, Symptomatic Status at Baseline,






n (%) (n5230) P
Previous myocardial infarction 118 (51.3) 109 (47.4) 0.79
Previous coronary bypass
surgery
33 (14.3) 31 (13.5) 0.97
Previous angioplasty 84 (36.5) 72 (31.3) 0.45
Unstable angina 105 (43) 94 (41) 0.60
Stable angina 119 (49) 116 (50) 0.75
Canadian class
1 5 (2) 4 (2) 0.79
2 47 (19) 47 (20) 0.76
3 58 (24) 52 (23) 0.74
4 9 (4) 13 (6) 0.29
Atypical chest pain 19 (8) 20 (9) 0.72
No. of diseased vessels
1 109 (47.4) 108 (47) 0.64
2 86 (37.7) 85 (37) 0.73
3 48 (20.9) 37 (16.1) 0.30
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creatine phosphokinase and its MB isoenzyme fraction. After dis-
charge, full blood counts (including platelet count) were performed
at 2 weeks, 1 month, and 6 weeks after stent implantation. Patients
assigned to oral anticoagulation had close monitoring of their
prothrombin time at the hospital outpatient clinic or by their general
practitioner. An outpatient visit was scheduled at 1 month, at which
time a physical examination was performed and an ECG obtained. A
final outpatient visit was scheduled 6 months after the procedure.
Coronary angiography, although optional, was recommended at
6-month follow-up.
Because ticlopidine therapy is associated, albeit rarely, with
leukopenia, thrombocytopenia, or agranulocytosis, and in view of the
limited experience with the use of ticlopidine in combination with
aspirin after coronary stenting, the following guidelines were pro-
posed if hematological abnormalities occurred during follow-up. If
the white cell count was between 1200 and 1700/mm3 or the platelet
count between 80 000 and 150 000/mm3, it was recommended that a
blood count be obtained every 2 days and the treatment continued. If
the white cell count fell to ,1200/mm3 and/or the platelet count to
,80 000/mm3, it was recommended that the treatment be stopped
and a blood count obtained 1 and 2 weeks later (or more frequently
if judged necessary).
If ticlopidine was discontinued, recommendations for subsequent
treatment were given depending on the duration of ticlopidine
treatment. If ticlopidine was stopped within 4 weeks of stent
implantation, it was recommended that oral anticoagulation be
instituted and continued until 6 weeks after stent implantation. If
ticlopidine was stopped .4 weeks after stent implantation it was
recommended that it be replaced by dipyridamole (450 mg daily)
until 6 weeks after stent implantation.
Primary Study End Points and Definitions
The primary end point of the study was the rate of bleeding
complications in the 6 weeks after stent implantation. Bleeding
complications were subdivided depending on whether they were
local complications (at the vascular access site) or occurred at
another site. Local complications were divided into ecchymoses,
hematomas, and false aneurysms. An ecchymosis was defined as
subcutaneous bleeding with discoloration of the skin around the
puncture site. Ecchymoses were subdivided depending on their size,
.5 or ,5 cm. A hematoma was defined as subcutaneous bleeding
around the puncture site that was accompanied by swelling. False
aneurysms, diagnosed by ultrasound, were subdivided in 2 groups
depending on whether surgical repair was undertaken. Other bleed-
ing events were intracranial bleeding, gastrointestinal bleeding,
intraocular bleeding, macroscopic hematuria (not related to urinary
catheterization), or any bleeding that required blood transfusion.
Secondary Study End Points and Definitions
The secondary end points were the rates of acute or subacute stent
occlusion, clinical cardiac-related events (death, Q-wave or non–Q
wave myocardial infarction) and the duration of hospitalization.
Acute stent occlusion was defined as stent occlusion occurring
within 24 hours of stent implantation. In the absence of angiographic
confirmation, the appearance of new Q waves, or an increase in the
creatine kinase concentration to 2 times the upper limit of normal
with a concomitant rise in the creatine kinase MB isoenzyme
(.10%) were considered as evidence of stent occlusion. Subacute
stent occlusion was defined as stent occlusion occurring .24 hours
after stent implantation. In the absence of angiographic confirmation,
the ECG and cardiac enzyme criteria (outlined above) were used. All
deaths were considered to be related to cardiac causes unless an
autopsy established a noncardiac cause. The diagnosis of acute
myocardial infarction (MI) was based on the occurrence of typical
chest pain, lasting .30 minutes, the appearance of new Q waves, or
an increase in the creatine kinase concentration to 2 times the upper
limit of normal with a concomitant rise in the creatine kinase MB
isoenzyme. The duration of hospitalization was counted from the day
of the procedure to the day of discharge (discharge after noon was
counted as a full day).







n (%) (n5230) P




116 (47.7) 121 (52.6) 0.28
De novo lesion 198 (81.5) 197 (85.7) 0.22
Restenotic lesion 45 (18.5) 33 (14.3) 0.22
RCA 102 (42) 86 (37) 0.30
LAD 35 (14.5) 32 (14) 0.87
LCx 84 (34.5) 96 (42) 0.11
SVG 22 (9) 16 (7) 0.40
Vessel diameter (mm)
,3.0 39 (16) 40 (17) 0.69
.3.0 204 (84) 190 (83) 0.34
No. of stents implanted
1 211 (86.4) 188 (81.7) 0.16
2 29 (12.3) 32 (13.9) 0.61




RCA indicates right coronary artery; LAD, left anterior descending coronary
artery; LCx, left circumflex coronary artery; and SVG, saphenous vein graft.










Ecchymosis (.5 cm) 16 (6.6) 38 (16.5) 0.006 0.36 (0.18–0.68)
Hematoma 25 (10.3) 34 (14.8) 0.13 0.66 (0.37–1.18)
False aneurysm 2 (0.8) 6 (2.6) 0.13 0.31 (0.04–1.74)
Surgical repair 1 (0.4) 2 (0.9) 0.52 0.47 (0.01–9.04)
Other bleeding 2 (0.8) 7 (3.0) 0.07 0.26 (0.04–1.40)
Transfusion 4 (1.6) 6 (2.6) 0.45 0.62 (0.14–2.51)
Any bleeding complication 33 (13.5) 48 (21) 0.03 0.59 (0.36–0.98)
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Statistical Analysis
The primary end point was the occurrence of bleeding complications
(defined in Methods). Given an estimated rate of 15% in the
population treated with conventional anticoagulation2 and assuming
that aggressive antiplatelet treatment is able to reduce bleeding
complications from 15% to ,5%, a sample size of 160 patients per
group would be required for this end point (allowing for an a error
of 0.05 and a b error of 0.20). It was decided to enroll 400 patients.
The statistical analysis was performed with use of the StatView
software program (StatView Inc). Baseline characteristics were
compared in the 2 groups by use of the t test, x2 test, or Fisher’s exact
test as appropriate. Clinical events related to the procedure and those
occurring during follow-up were compared with the x2 test or the
Mantel-Haenszel test on ordered categories, as appropriate. When
.1 clinical event occurred per patient, the most severe event was
used for the analysis.
Results
Baseline Characteristics, Indications for Stenting,
and Procedural Variables
Thirteen European centers (listed in the Appendix) partici-
pated in this trial. Between May 1995 and May 1996, they
enrolled 485 patients: 249 were randomized to antiplatelet
therapy and 236 were randomized to conventional anticoag-
ulation. Stent implantation was not possible in 4 patients (3
randomized to treatment with ticlopidine and aspirin and 1
randomized to conventional anticoagulation) and 3 were
referred for emergency coronary artery bypass surgery (1
randomized to antiplatelet therapy and 2 randomized to
conventional anticoagulation). Five patients withdrew in-
formed consent. Thus, the final cohort for the per protocol
analysis comprised 473 patients (243 in the antiplatelet
therapy group and 230 in the conventional anticoagulation
group). Baseline characteristics of the population, including
the distribution of risk factors for coronary disease, are
presented in Table 1. Cardiac history, baseline symptoms, and
the extent of coronary disease are presented in Table 2. Stent
placement (Table 3) was performed electively in 52.3% of
patients randomized to antiplatelet therapy and in 47.4% of
patients randomized to conventional anticoagulation
(P50.25), and was unplanned in 48% of patients randomized
to antiplatelet therapy and in 53% of patients randomized to
conventional anticoagulation (P50.55). The proportion of
patients in whom stents were implanted for restenosis was
similar in patients randomized to conventional anticoagula-
tion or to antiplatelet therapy (P50.22). There were no
significant differences between groups with respect to mean
vessel diameter adjacent to the stented site, the number of
stents implanted, or the maximum inflation pressure used to
impact the stent (Table 3).
Primary End Points
The bleeding complications are presented in Table 4. There
was a significant decrease in the occurrence of significant
ecchymoses (.5 cm diameter) in patients randomized to
antiplatelet therapy (P50.006). Major bleeding (P50.07) and
false aneurysm formation (P50.13) were less frequently









Acute stent occlusion 6 (2.4) 1 (0.4) 0.06 0.17 (0.01–1.45)
Subacute stent occlusion 1 (0.4) 8 (3.5) 0.01 0.12 (0.01–0.91)
Death 2 (0.8) 4 (1.7) 0.37 0.47 (0.06–3.00)
Q-wave myocardial infarction 3 (1.2) 6 (2.6) 0.27 0.47 (0.09–2.13)
Non–Q wave myocardial infarction 9 (3.7) 9 (3.9) 0.9 0.94 (0.34–2.65)
Hospital stay, d6SD 4.363.6 6.463.7 0.0001
TABLE 6. Major Cardiac Clinical Events: Effects of Indication







Elective stenting (n5123) (n5110)
Death 1 (0.8) 1 (0.9)
Acute myocardial infarction 2 (1.6) 10 (9)
Q wave 0 (0) 4 (3.6)
Non–Q wave 2 (1.6) 6 (5.4)
Total cardiac-related events 3 (2.4) 11 (9.9) 0.01
Unplanned stenting (n5120) (n5120)
Death 1 (0.8) 4 (3.3)
Acute myocardial infarction 10 (6.9) 5 (4.1)
Q wave 3 (2.5) 2 (1.7)
Non–Q wave 7 (5.8) 3 (2.7)
Total cardiac-related events 11 (8.9) 9 (8.1) 0.6
Optimal result after stenting (n5225) (n5209)
Death 2 (0.9) 4 (1.9)
Acute myocardial infarction 10 (4.5) 13 (6.2)
Q wave 3 (1.3) 6 (2.9)
Non–Q wave 7 (3.1) 7 (3.3)
Total cardiac-related events 12 (5.3) 17 (8.1) 0.24
Suboptimal result after stenting (n518) (n521)
Death 0 (0) 0 (0)
Acute myocardial infarction 2 (11.1) 2 (9.5)
Q wave 0 (0) 0 (0)
Non–Q wave 2 (11.1) 2 (9.5)
Total cardiac-related events 2 (11.1) 2 (9.5) 0.87
Optimal result after stenting: residual stenosis ,30%, no residual dissec-
tion, and no evidence of thrombus. Suboptimal result after stenting (any of the
following): residual stenosis .30%, presence of residual dissection, or
presence of thrombus.
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observed in patients randomized to antiplatelet therapy. The
rate of surgical repair was similar in both groups. Overall,
bleeding complications were significantly less frequent in the
antiplatelet therapy group with a risk reduction of 41% (95%
CI, 0.35 to 0.98).
Secondary End Points
The overall rate of stent occlusion (Table 5) did not differ
significantly (P50.53) between the group randomized to
antiplatelet therapy (2.8%) and the group randomized to
conventional anticoagulation (3.9%). However, acute (,24
hours) stent occlusion was more frequent (P50.06) in the
group randomized to antiplatelet therapy (2.4% versus 0.4%)
whereas subacute (.24 hours) stent occlusion was more
frequent (P50.01) in the group randomized to conventional
anticoagulation (3.5% versus 0.4%). All the subacute occlu-
sions occurred within 1 week of the procedure.
The cardiac events occurring in the 2 groups during the
procedure and the subsequent 6 weeks are presented in Table
5. Six patients died: 3 of acute MI after stent occlusion, 1
suddenly, 1 of a cerebrovascular accident, and 1 of renal
failure. There were 2 deaths (0.8%) in the group randomized
to antiplatelet therapy and 4 (1.7%) in the group randomized
to conventional anticoagulation (P50.37). Q-wave MI oc-
curred in 3 patients (1.2%) randomized to antiplatelet therapy
and 6 patients (2.6%) randomized to conventional anticoag-
ulation. There was a lower overall cardiac event rate in the
group randomized to antiplatelet therapy (5.7%) than in the
group randomized to full anticoagulation (8.3%), but the
difference was not statistically significant (P50.37).
Duration of Hospitalization
Patients randomized to antiplatelet therapy had a significantly
(P,0.00001) shorter hospital stay (4.363.6 days; median, 3
days; range, 1 to 29 days) than those randomized to conven-
tional anticoagulation (6.463.4 days; median, 6 days; range,
1 to 29 days).
Indication for Stenting and Immediate
Angiographic Result: Effects on Outcome
In patients who underwent elective stenting, the overall rate
of cardiac-related events was significantly (P,0.01) less in
the group randomized to antiplatelet therapy than in the group
randomized to full anticoagulation (Table 6). No such differ-
ence was observed in patients for whom stenting was
unplanned.
Side Effects
In the group treated with antiplatelet therapy, rashes occurred
in 3.3% of patients and gastrointestinal side effects in 2.4% of
patients. Leukopenia, with a total white cell count ,3000,
occurred in 4 patients (1.6%) treated with antiplatelet therapy,
but none of these cases were severe (white cell count ,1200).
Ticlopidine treatment was stopped because of side effects in
13 patients (5.2%) treated with antiplatelet therapy.
Six-Month Follow-up
The cumulative totals of clinical events in both groups at
6-month follow-up is presented in Table 7. There was no
significant difference between the groups. Four hundred
patients were free of events (death, MI, or revascularization)
at 6 months. The rate of target vessel revascularization was
low and similar in both groups.
Discussion
The implantation of metallic coronary stents has increased
dramatically in recent years. This reflects not only the
perceived benefit of stent implantation in the prevention of
restenosis, which has only been conclusively demonstrated in
patients with new lesions in native vessels .3.00 mm in
diameter,1,2 but also the increasing complexity of lesions for
which angioplasty is attempted. The high rate of stent
occlusion documented in the early experience with coronary
stenting has decreased in recent years. However, the rate of
subacute stent occlusion in patients treated with conventional
anticoagulation, '4% of patients, represents a major clinical
concern as subacute occlusion almost invariably results in
death or acute MI.7
Recent clinical studies have had a major impact on the
management of patients after stent implantation. Using intra-
vascular ultrasound, Columbo and colleagues3 showed that
stents were often inadequately impacted in the vessel wall
and that further balloon inflation at pressures as high as 20
atm (with appropriately sized balloons) was required to
ensure optimal stent expansion. They further demonstrated
that high pressure–assisted stent implantation accomplished
without intravascular ultrasound guidance and subsequent
anticoagulation was safe and associated with a low risk of
subacute stent occlusion.4 In a recent pooled analysis,8 stent-
related thrombosis occurred in only 33 of 2630 patients who
did not receive anticoagulant therapy. The majority of the
patients in this report did not have ultrasound-guided stent
implantation whereas high-pressure inflation was commonly
used.
Only 2 major randomized studies (Scho¨mig et al9 and
STARS10) have compared antiplatelet therapy alone with
conventional anticoagulation in the management of patients
after stent implantation. The anticoagulation strategy and the
antiplatelet therapy used were similar to those in the present
trial. However, although a different stent was used in the 2
studies, there were important differences in the study design.
First, randomization was performed in these trials after
successful stent implantation and only patients with an








Death 2 (0.8) 5 (2.2) 0.21
Acute myocardial infarction 13 (5.4) 16 (7.1) 0.44
Q wave 3 (1.2) 7 (3.1) 0.16
Non–Q wave 10 (4.1) 9 (4.0) 0.93
Coronary artery bypass surgery 3 (1.2) 3 (1.3) 0.93
Repeat target lesion angioplasty 13 (5.4) 11 (4.9) 0.80
Total 31 (12.9) 35 (15.5) 0.40
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optimal angiographic result after stent implantation were
enrolled. In the present study, randomization was performed
before stent implantation was attempted. Patients were con-
tinued in the trial regardless of whether the result (after stent
implantation, as assessed by angiography) was optimal.
Second, although the ISAR study9 was a single-center study,
the STARS10 and the present study were multicentric. STARS
is the most complete study, because 3 different strategies
were compared: aspirin alone, aspirin in conjunction with oral
anticoagulation, and aspirin in conjunction with ticlopidine.
The results are unequivocal: the rate of stent occlusion was
significantly lower with aspirin and ticlopidine (0.6%) than
with conventional anticoagulation (2.5%) and aspirin alone
(3.6%).
The results of the present study, in agreement with the
results of the Scho¨mig et al9 and the STARS10 trials and of
numerous observational studies, demonstrate that the use of
antiplatelet therapy alone after stent implantation is associ-
ated with a reduction in the overall rate of bleeding compli-
cations and in the rate of subacute stent occlusion. However,
the overall mortality and nonfatal MI rates did not differ
significantly between patients treated with antiplatelet ther-
apy alone and those treated with conventional anticoagulant
therapy. The use of antiplatelet therapy to manage stent
implantation and the simplicity of the treatment regimen has
led cardiologists to treat more complex lesions, secure in the
knowledge that elective or bailout stent implantation can be
safely achieved. Bleeding complications, the primary study
end point, were less frequent with antiplatelet therapy. Al-
though the only significantly different bleeding complication
was large ecchymosis, a trend toward a lower rate of more
serious bleeding was also observed (0.8% versus 3.0%,
P50.07). The avoidance of anticoagulation therapy may be
the major contributor to the lack of bleeding in the group
treated with antiplatelet therapy.
The results of the present study show that, even with
antiplatelet therapy, there is still a significant morbidity
associated with coronary stent implantation. In the era of
conventional anticoagulation, the major source of coronary
morbidity was subacute occlusion in the week after stent
implantation. With antiplatelet therapy, coronary morbidity is
almost exclusively related to acute occlusion in the 24 hours
after the procedure. In the present study, acute stent occlusion
occurred in 1.7% of the entire population and was more
common (P50.06) in the antiplatelet therapy group (2.4%)
than in the conventionally treated group (0.4%).
The mechanisms of acute stent occlusion are incompletely
understood. However, observational studies4,10 have demon-
strated that a suboptimal result after stent implantation
(significant residual stenosis, residual dissection, or angio-
graphic evidence of thrombus) is associated with acute stent
occlusion that may be a consequence of distal extension of
residual dissection, superimposed thrombosis, or a combina-
tion of both these mechanisms. In the present study, the
overall rate of cardiac events in patients in whom stent
implantation was electively performed was significantly less
in the group treated with antiplatelet therapy. No such
difference was observed for patients in whom stent implan-
tation was performed for a suboptimal result after balloon
angioplasty or to salvage failed angioplasty. Finally, the rate
of cardiac events was higher in patients with a suboptimal
result after stenting (10.3%, 4 of 39 patients) than in patients
with optimal stent implantation (6.7%, 29 of 234 patients),
although the number of patients with a suboptimal result was
small. Obviously, these observations result from a post hoc
analysis with the limitations inherent to such an analysis.
However, this information is of potential interest because the
appropriate management (in particular, the role of antiplatelet
therapy) of patients with suboptimal results is unclear. In-
deed, the vast majority of studies of antiplatelet therapy after
stent implantation, including the only other randomized study
to date, have specifically excluded this patient population.4,9,11,12
The present study shows that acute stent occlusion may
also occur in the absence of mechanical predisposing factors
such as residual dissection. Indeed, in 2 of the 6 cases of acute
occlusion in the antiplatelet group, the procedure was uncom-
plicated and the angiographic result optimal. Such occlusions
are likely related to thrombus formation at the stented site, a
hypothesis that is supported by the observation that only 1
occlusion occurred in the conventionally anticoagulated
group and by the observation that the peak antiplatelet effect
of ticlopidine therapy is observed only after 72 hours of
treatment.13,14 In the present study, as in common clinical
practice, ticlopidine was given only after the procedure. It is
also possible that acute thrombosis in the antiplatelet treat-
ment group could have been related to the lack of continued
anticoagulation.
In summary, the present study demonstrates that antiplate-
let therapy reduces the rate of subacute stent occlusion
compared with conventional anticoagulation therapy. How-
ever, stent occlusion in the 24 hours after the procedure
remains a problem. Pretreatments with both ticlopidine and
aspirin or the use of other potent antiplatelet agents, such as
inhibitors of glycoprotein IIb/IIIa, represent potential ap-
proaches that may help to further reduce stent-related mor-
bidity and mortality. Such approaches could be applied
indiscriminately or only in high-risk groups; furthermore,
such treatments expose patients to an increased risk of
bleeding, and the cost of the newer antiplatelet agents
presents potential economic difficulties. The answers to these
questions will require further randomized trials.
Appendix
Principal Investigators and Participating Centers
Number of patients is listed in parentheses.
Belgium
Dr V. Legrand, CHU Sart Tilman, B-4000 Lie`ge (90); Dr J. Boland,
Hoˆpital de la Citadelle, Boulevard du 12ie`me de Ligne, B-4000 Lie`ge
(65); Dr M. Vrolix, OCMW St Jans Hospital, Schiepsebos 2, B-3600
Genk (50); and Dr L. Missault, Academisch Ziekenhaus St Jan,
Ruddershove 10, B-8000 Brugge (39).
Germany
Dr E. Fleck, Deutsches Herzzentrum Berlin, Augustenburger Platz 1,
13353 Berlin (60).
Italy
Dr S. Chierchia, Ospedale San Raffaele, Via Olgettina 60, 20090
Segrate, Milan (30); Dr Cassaccia, Azienda Ospidaliera F. Giovan,
Corsa Bramente 88, I-10100 Torino (19); and Dr Niccoli, Azienda
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Ospedaliera Speciale Civili, Piazzale Speciali Civili 1, I-25123
Brescia (9).
The Netherlands
Dr H. Bonnier, Catharina Ziekenhuis, Michelangelolaan 2, 5623 EJ
Eindhoven (56).
Sweden
Dr H. Emmanuelson, Sahlgrenska Hospital, S-41345 Goteborg (54).
Turkey
Dr Ali Oto, Hacettepe University Hospital, 0610 Ankara, Turkey (6).
United Kingdom
Dr C. White, HCI Medical, Beardmore St, Clydebank G81 4HX,
Scotland (4); Dr M. Webb Peploe, St Thomas Hospital, Lambeth
Palace Rd, London SE1 7EH (3).
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